
Coherus BioSciences Inc
NASDAQ:CHRS

Intrinsic Value
The intrinsic value of one
CHRS
stock under the Base Case scenario is
3.65
USD.
Compared to the current market price of 0.79 USD,
Coherus BioSciences Inc
is
Undervalued by 78%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Coherus BioSciences Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Coherus BioSciences Inc
Balance Sheet Decomposition
Coherus BioSciences Inc
Current Assets | 310.2m |
Cash & Short-Term Investments | 82.4m |
Receivables | 62.4m |
Other Current Assets | 165.3m |
Non-Current Assets | 60.9m |
PP&E | 2.3m |
Intangibles | 53m |
Other Non-Current Assets | 5.7m |
Free Cash Flow Analysis
Coherus BioSciences Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Coherus BioSciences Inc
Revenue
|
197.5m
USD
|
Cost of Revenue
|
-85.6m
USD
|
Gross Profit
|
111.9m
USD
|
Operating Expenses
|
-216.1m
USD
|
Operating Income
|
-104.3m
USD
|
Other Expenses
|
-26.7m
USD
|
Net Income
|
-130.9m
USD
|
CHRS Profitability Score
Profitability Due Diligence
Coherus BioSciences Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

Score
Coherus BioSciences Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
CHRS Solvency Score
Solvency Due Diligence
Coherus BioSciences Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Score
Coherus BioSciences Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CHRS Price Targets Summary
Coherus BioSciences Inc
According to Wall Street analysts, the average 1-year price target for
CHRS
is 5.37 USD
with a low forecast of 1.06 USD and a high forecast of 7.35 USD.
Dividends
Current shareholder yield for CHRS is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
CHRS
stock under the Base Case scenario is
3.65
USD.
Compared to the current market price of 0.79 USD,
Coherus BioSciences Inc
is
Undervalued by 78%.